
Kalpana Mujoo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4442574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of nitric oxide signaling components in differentiation of embryonic stem cells into myocardial cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18924-18929.	7.1	96
2	Regulation of ERBB3/HER3 signaling in cancer. Oncotarget, 2014, 5, 10222-10236.	1.8	90
3	Role of soluble guanylyl cyclase–cyclic GMP signaling in tumor cell proliferation. Nitric Oxide - Biology and Chemistry, 2010, 22, 43-50.	2.7	57
4	Nitric oxide–cyclic GMP signaling in stem cell differentiation. Free Radical Biology and Medicine, 2011, 51, 2150-2157.	2.9	44
5	Differential Expression of Nitric Oxide Signaling Components in Undifferentiated and Differentiated Human Embryonic Stem Cells. Stem Cells and Development, 2006, 15, 779-787.	2.1	36
6	Synthesis and secretion of alpha-fetoprotein and albumin by newborn rat brain cells in culture. Developmental Brain Research, 1982, 6, 47-55.	1.7	33
7	Differentiation of Human Induced Pluripotent or Embryonic Stem Cells Decreases the DNA Damage Repair by Homologous Recombination. Stem Cell Reports, 2017, 9, 1660-1674.	4.8	33
8	Phase Ia/Ib Trial of Anti-GD2 Chimeric Monoclonal Antibody 14.18 (ch l4.18) and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in Metastatic Melanoma. Journal of Immunotherapy, 1996, 19, 206-217.	2.4	32
9	An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunology, Immunotherapy, 1995, 40, 322-328.	4.2	31
10	Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. Journal of Cancer Research and Clinical Oncology, 2003, 129, 709-718.	2.5	29
11	A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunology, Immunotherapy, 1991, 34, 198-204.	4.2	28
12	Curcumin induces differentiation of embryonic stem cells through possible modulation of nitric oxide-cyclic GMP pathway. Protein and Cell, 2012, 3, 535-544.	11.0	28
13	Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunology, Immunotherapy, 1995, 40, 339-345.	4.2	24
14	Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer. Oncotarget, 2016, 7, 65758-65769.	1.8	17
15	β2-spectrin depletion impairs DNA damage repair. Oncotarget, 2016, 7, 33557-33570.	1.8	17
16	Nitric Oxide Receptor Soluble Guanylyl Cyclase Undergoes Splicing Regulation in Differentiating Human Embryonic Cells. Stem Cells and Development, 2011, 20, 1287-1293.	2.1	14
17	Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells. Cancer Immunology, Immunotherapy, 1996, 42, 115-121.	4.2	13
18	Role of the Exocyst Complex Component Sec6/8 in Genomic Stability. Molecular and Cellular Biology, 2015, 35, 3633-3645.	2.3	13

Kalpana Mujoo

#	Article	IF	CITATIONS
19	Pluripotent Stem Cells and DNA Damage Response to Ionizing Radiations. Radiation Research, 2016, 186, 17-26.	1.5	11
20	Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog. Prostate, 2005, 62, 91-100.	2.3	10
21	Crk II silencing down-regulates IGF-IR and inhibits migration and invasion of prostate cancer cells. Biochemistry and Biophysics Reports, 2016, 8, 382-388.	1.3	9
22	Tumor Necrosis Factor ?? and ?? Interferon Enhancement of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Binding to Human Melanoma Cells. Journal of Immunotherapy, 1993, 13, 166-174.	2.4	7
23	Isolation, Characterization, and Synthesis of AlphaFetoprotein from Neonatal Rat Brain. Journal of Neurochemistry, 1983, 41, 1223-1228.	3.9	6
24	An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunology, Immunotherapy, 1995, 40, 322-328.	4.2	5
25	Nuclear functions of Î ² 2-Spectrin in genomic stability. Aging, 2016, 8, 3151-3152.	3.1	1
26	Therapeutics of Oxidative Stress and Stemness in Breast Cancer. , 2022, , 1765-1776.		0